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Abstract
Therapeutic resistance remains the principal problem in acute myeloid leukemia (AML). We used 
area under receiver operator characteristic curves (AUC) to quantify our ability to predict 
therapeutic resistance in individual patients where AUC=1.0 denotes perfect prediction and 
AUC=0.5 denotes a coin flip, using data from 4,601 patients with newly diagnosed AML given 
induction therapy with 3+7 or more intense standard regimens in MRC/NCRI, HOVON, SWOG, 
and MD Anderson Cancer Center studies. Age, performance status, white blood cell count, 
secondary disease, cytogenetic risk, and FLT3-ITD/NPM1 mutation status were each 
independently associated with failure to achieve complete remission despite no early death 
(“primary refractoriness”). However, the AUC of a bootstrap-corrected multivariable model 
predicting this outcome was only 0.78, indicating only fair predictive ability. Removal of FLT3-
ITD and NPM1 information only slightly decreased the AUC (0.76). Prediction of resistance, 
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defined as primary refractoriness or short relapse-free survival (RFS), was even more difficult. 
Our ability to forecast resistance based on routinely available pre-treatment covariates provides a 
rationale for continued randomization between standard and new therapies and supports further 
examination of genetic and post-treatment data to optimize resistance prediction in AML.
Keywords
Acute myeloid leukemia; area under the receiver operator characteristic curve; prediction; 
therapeutic resistance
INTRODUCTION
“Resistance”, defined as either failure to achieve initial complete remission (CR) or as 
relapse from CR, remains the principal problem in adult acute myeloid leukemia (AML).1–3 
It is widely appreciated that the likelihood of resistance to therapy differs significantly 
between individuals; e.g., the complete remission (CR) rate following initial chemotherapy 
is 80–90% in some patients but below 30% in others.4, 5
The ability to accurately forecast resistance would have considerable significance for the 
management of AML and the evaluation of new drugs. Specifically, the better our ability to 
predict resistance to standard therapy, the less need there might be for randomization of 
patients between such therapy and an investigational therapy. The lack of a need to 
randomize would address a seldom discussed but very real ethical conundrum: physicians 
caring for AML patients generally are not enthusiastic about randomizing patients with 
features associated with resistance (older age, complex cytogenetics, secondary AML, etc.) 
to standard therapy but are willing to do so because they believe that our ability to predict 
resistance to standard therapy is only fair and, thus, that randomization is necessary to 
properly evaluate a new therapy. We therefore set out to test this belief by quantifying our 
current ability to predict resistance.
Here, it may be important to distinguish between association and prediction. It is well 
known that clinical, cytogenetic, and molecular characteristics are strongly associated with 
resistance,1–3 as quantified by odds ratios, hazard ratios, and P-values, the standard 
measurements of association.6 While valuable, these traditional measurements do not give 
insight into the degree to which given prognostic factors improve our ability to predict 
outcome in individual patients. This is the province of measures of prediction such as the 
area under receiver operating curve (AUC).7 Conceptually, the closer we are to AUCs of 
1.0, the less need there might be to randomize patients between standard therapy (i.e. 
therapy for which the outcome can be predicted) and a novel therapy. Herein, we use AUCs 
in conjunction with clinical, cytogenetic, and molecular data from adults with newly 
diagnosed AML treated on trials conducted by the U.K. Medical Research Council/National 
Cancer Research Institute (MRC/NCRI), the Dutch-Belgian Cooperative Trial Group for 
Hematology/Oncology and the Swiss Group for Clinical Cancer Research (HOVON/
SAKK), the U.S. cooperative group SWOG, and MD Anderson Cancer Center (MDA) to 
quantify our ability to predict therapeutic resistance using uni- and multiparameter models.
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MATERIALS AND METHODS
Study population and treatments
The trials we analyzed primarily enrolled adults with newly diagnosed AML other than 
acute promyelocytic leukemia, as based on WHO 2008 classification criteria.8 Specifically, 
we used data from patients who received curative-intent treatment on 6 MRC/NCRI trials 
from 1988–2010 (AML10, AML11, AML12, AML14, AML15, and AML16), 6 HOVON/
SAKK trials from 1987–2008 (HO04, HO04A, HO29, HO42A, HO42, and HO43), or 4 
SWOG trials from 1992–2009 (S8931, S93333, S9500, and S0106), or received treatment 
on various protocols at MDA from 2000–2013. As expected, there were intergroup 
differences with regard to the type of therapeutic regimens used: for example, while 
induction treatments generally contained cytarabine and daunorubicin or idarubicin, therapy 
at MDA more often included cytarabine at >1 g/m2/dose, while in MRC/NCRI typically 10 
rather than 7 days of cytarabine at 100–200 mg/m2/dose were used; moreover, HOVON/
SAKK post remission therapy often included amsacrine. Institutional review boards of 
participating institutions approved all protocols, and patients were treated according to the 
Declaration of Helsinki.
Definitions of outcomes
Early death (“treatment-related mortality” [TRM]) was defined as death within 28 days after 
initiating therapy9 or study registration, if exact date of initiation of therapy was unknown. 
Complete remission (CR) was conventionally defined as achievement of a morphologic 
leukemia-free state (bone marrow blasts <5%, absence of extramedullary disease) and 
recovery of peripheral blood counts (absolute neutrophil count >1,000/μL and platelet count 
>100,000/μL).2, 10 Overall survival (OS) was defined as time from initiation of therapy or 
study registration (if date of initiation of therapy was unknown) to death, with censoring on 
the day patients were last known to be alive. For patients who achieved CR, relapse-free 
survival (RFS) was defined as time from achievement of remission until relapse or death 
from any cause, with patients not known to have relapsed or died being censored at last 
follow-up.
Rather than settling on a single, arbitrary criterion to define therapeutic resistance, we used 
several criteria for resistance: (a) failure to attain CR despite surviving at least 28 days from 
beginning induction therapy (“primary refractory”); (b) primary refractory or RFS ≤3 
months; (c) primary refractory or RFS ≤6 months; and (d) primary refractory or RFS ≤12 
months.
Statistical analysis
OS and RFS were estimated using the Kaplan-Meier method.11 Chi-squared tests and the 
Kruskal-Wallis test were used to assess differences between categorical variables and 
median values of numeric variables across categories, respectively. We used logistic 
regression analyses to assess the relationship between individual covariates and various 
working definitions of therapeutic resistance, and then used the AUC to quantify a model’s 
ability to predict therapeutic resistance; in this approach, an AUC of 1 indicates perfect 
prediction while an AUC of 0.5 indicates no prediction. It is natural to wonder whether some 
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of the changes in AUC observed, for example from 0.77 to 0.78, are “statistically 
significant”; however, there is no rule permitting one to say whether a given change in AUC 
is statistically significant. Rather, this depends on effect size and patient numbers. Given the 
large number of models we evaluated and the even larger number of pairwise comparisons, 
we consider it more important to focus on the magnitude of AUC values and changes in 
these values (rather than on their statistical significance) using the commonly accepted 
criteria that AUCs of 0.6–0.7, 0.7–0.8, and 0.8–0.9 indicate poor, fair, and good predictive 
ability, respectively.12–14 An alternative way of interpreting AUC is as the proportion of 
patients who are correctly ranked. For example, a model with an AUC of 0.85 correctly 
ranks patients with higher risk has having a larger risk score 85% of the time, so 15% of the 
time the model incorrectly gives a person with higher risk a lower risk score than a person 
with lower risk. In this interpretation, the AUC is linear: a model with an AUC of 0.75 is a 
25% improvement over a model with an AUC of 0.50. The following pre-treatment 
covariates were used in the regression modeling: age at study registration, performance 
status, gender, white blood cell (WBC) count, platelet count, bone marrow blast percentage, 
disease type (primary vs. secondary), cytogenetic risk, and FLT3-ITD as well as NPM1 
mutational status. Missing cytogenetic risk was accounted for as separate category. The 
relative importance of predictors in the multivariable regression models was evaluated by 
the value of the partial Wald Chi-squared statistic minus the predictor’s degrees of freedom. 
Bootstrapping, which has been demonstrated to be a more efficient method for assessing 
internal model accuracy than cross-validation or splitting data into two groups,15, 16 was 
used to estimate bias-corrected values of AUC, and all reported AUCs are bootstrap-bias 
corrected. All analyses were performed using R (http://www.r-project.org).
RESULTS
Characterization of study population
Our dataset included 4,955 predominantly adults with newly diagnosed AML treated on 
MRC/NCRI, HOVON/SAKK, or SWOG protocols or given treatment at MDA and in whom 
pre-treatment information (age, gender, performance status, WBC and platelet count, bone 
marrow blast percentage, secondary AML, FLT3-ITD and NPM1 mutational status) and 
outcome data were available. To better assess resistance following initial chemotherapy, we 
excluded patients who died within 28 days of initiation of induction chemotherapy (n=335) 
or were lost to follow-up before this time (n=19), leaving 4,601 patients (median age: 52 
years) from our 4 treatment sites (MRC/NCRI [n=2,615], HOVON/SAKK n=1,134], SWOG 
[n=443], and MDA [n=409]). Patients’ baseline characteristics are presented in Table 1. As 
summarized in Table 2, a CR to the initial 1–2 courses of induction chemotherapy was 
achieved in 3,613 (79%) of patients, whereas 988 (21%) were “primary refractory”. 
1,318/4,552 patients (29%) with sufficient follow-up time were either primary refractory or 
had a RFS of 3 months or less after CR achievement, 1,784/4,503 patients (40%) with 
sufficient follow-up time were either primary refractory or had a RFS of 6 months or less 
after CR achievement, and 2,547/4,457 patients (57%) with sufficient follow-up time were 
primary refractory or had a RFS of 12 months or less after CR achievement.
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Prediction of failure to achieve CR with initial induction chemotherapy
Patients with primary refractory AML are widely considered those exhibiting the highest 
degree of resistance. Not surprisingly, but serving as a data reliability check, age (P<0.001), 
performance status (P=0.006), WBC (P<0.001), secondary disease (P<0.001), cytogenetic 
risk (favorable or intermediate vs. adverse; P<0.001 for each comparison), and NPM1 
mutation as well as FLT3-ITD status (NPM1neg/FLT3-ITDneg or NPM1neg/FLT3-ITDpos vs. 
NPM1pos/FLT3-ITDpos; P<0.005 for each comparison) were independently associated with 
being primary refractory to induction chemotherapy when considering all patients (Table 3). 
As shown in Figure 1A, age was the most important individual covariate in predicting 
failure to achieve CR followed by cytogenetic risk and NPM1 and FLT3/ITD status, as 
indicated by values of the partial Wald Chi-squared statistic. Despite the strong associations 
between such covariates and primary refractory AML, AUCs validated by bootstrap-
adjustment suggested that the predictive ability was less impressive. Specifically, in 
univariate models, AUC values were 0.68, 0.66, and 0.60 for age, cytogenetic risk, and 
NPM1 and FLT3-ITD mutational status, A bootstrap-corrected multivariable model 
incorporating all covariates (age, performance status, WBC, platelet count, bone marrow 
blast percentage, gender, disease type [primary vs. secondary], cytogenetic risk, and FLT3-
ITD as well as NPM1 mutational status) yielded an AUC of 0.78. Despite their strong 
associations with primary refractory AML, removal of FLT3-ITD and NPM1 from the 
model, while having a statistically significant effect on AUC, only decreased the AUC 
slightly (from 0.78 to 0.76; see Supplemental Figure 1). AUCs varied considerably among 
the 4 treatment sites: from 0.82/0.81 (with/without FLT3-ITD and NPM1 mutation 
information) to 0.69/0.66.
We performed several additional analyses of prediction of primary refractory AML. First, 
because information on the mutational status of FLT3 and NPM1 is currently thought to be 
clinically most helpful to guide decision-making in patients with cytogenetically normal 
AML, we restricted our analysis to patients with normal karyotypes at diagnosis. Here, the 
multivariable models with or without NPM1 and FLT3-ITD information for the combined 
dataset yielded AUCs of 0.75 and 0.72, respectively, with AUCs for the individual treatment 
sites of 0.72-0.81 (with inclusion of FLT3-ITD and NPM1) and 0.63–0.80 (without inclusion 
of FLT3-ITD and NPM1). Thus, these AUC values were not higher than the values in the 
unrestricted dataset presented above, and only in 1 of the 4 individual cohorts did the 
inclusion of FLT3-ITD and NPM1 mutational information improve the prediction 
performance of the models compared to models incorporating all cytogenetic groups. In the 
U.S., selection of induction chemotherapy for newly diagnosed AML is commonly made 
before cytogenetic and mutational information is available. For a second additional analysis 
aimed at evaluating AUCs under these circumstances, we built multivariable models without 
inclusion of molecular or cytogenetic information. The accuracy of such models was 
significantly lower, as indicated by the AUC obtained in the entire patient cohort of 0.70, 
with AUCs for the individual 4 treatment sites ranging from 0.59 to 0.78. Third, we 
examined whether predictive accuracy was improved if we focused on relatively 
homogeneous subsets. However, an analysis limited to our 3,942 patients with de novo 
AML yielded bootstrap-corrected AUCs of only 0.75 and 0.73 for multivariable models with 
or without NPM1 and FLT3-ITD information, i.e. lower than in our entire study cohort (0.78 
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and 0.76). Similarly restricting attention separately to patients aged 60 years or younger 
(n=3,425) and those older than 60 years (n=1,176), AUCs again were not higher than those 
in the entire study cohort (0.76/0.72 [younger patients] and 0.73/0.73 [older patients] for 
multivariable models with or without NPM1 and FLT3-ITD information, respectively). 
Finally, because recent studies indicated that many patients can achieve CR with an identical 
second course of chemotherapy after a first course failed,17 we restricted our analysis to 
patients declared primary refractory only after 2 courses of chemotherapy. Information on 
receipt of 1 vs. 2 cycles of induction therapy was only available in the SWOG cohort, in 
which 62 patients failed the first course of induction chemotherapy and did not receive re-
induction on protocol. In a subset analysis on the remaining 381 patients, bootstrap-
corrected AUCs were 0.66 and 0.64 for multivariable models with or without NPM1 and 
FLT3-ITD information, i.e. values that were lower than in the entire SWOG cohort (0.69 
and 0.66, respectively).
Prediction of failure to achieve CR or to have short RFS
To assess whether the results were similar when we used other criteria for resistance, we 
performed additional analyses in which we considered resistance not only as primary 
refractory AML but also as an RFS of no more than 3, 6, or 12 months from date of first CR. 
As shown in Figures 1A–D, the relative importance of individual covariates changed slightly 
when the criterion for resistance was altered, with FLT3-ITD and NPM1 mutational status 
and cytogenetic risk gradually replacing age as the most important individual covariates. As 
the time over which prediction was attempted increased, predictive ability decreased. 
Specifically, when analyzing the entire study cohort, the AUCs for models predicting 
primary refractory disease or to have RFS of ≤3, ≤6, or ≤12 months were 0.75/0.74 (with/
without inclusion of FLT3-ITD and NPM1 mutational data; Table 4 and Supplemental Table 
2), 0.76/0.73 (Table 5 and Supplemental Table 3), and 0.75/0.71 (Table 6 and Supplemental 
Table 4), respectively, vs. 0.78/0.76 when considering primary refractory AML alone.
Inclusion of patients who incurred TRM
Although our previous data suggest that 28 days is a reasonable criterion for distinguishing 
patients who fail therapy because of TRM,9 it is plausible that patients who die between 
days 14 and 28 had sufficient AML present at death that they would have been considered 
resistant had they lived beyond day 28. Hence, exclusion of patients who died before day 28 
might affect conclusions. We therefore performed additional analyses in which we included 
the 7% of our patients (354/4955) who died before day 28 or were lost to follow-up before 
that time. As summarized in Table 7, the conclusions were essentially unaffected by 
inclusion of these patients, with AUCs for models predicting primary refractory disease or to 
have RFS of ≤3, ≤6, or ≤12 months being 0.77, 0.75, 0.76, and 0.75, respectively, when 
mutational data on FLT3-ITD and NPM1 were included.
AUCs in specific cytogenetic risk groups
One might suspect that the ability to predict resistance is higher in patients with high-risk or, 
conversely, favorable cytogenetics. To test this possibility, we performed separate analyses 
of resistance in favorable-risk, intermediate-risk, and unfavorable-risk cytogenetic groups. 
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However, there was no evidence that AUCs differed in different cytogenetic risk groups 
regardless of whether FLT3-ITD and NPM1 data were included. Even in the unfavorable-
risk group AUCs remained relatively low for models predicting primary refractory disease 
or to have RFS of ≤3, ≤6, or ≤12 months (0.64–0.65).
DISCUSSION
AML patients fail to be cured primarily because of resistance to therapy. The dominant role 
of resistance has been noted previously for patients during induction18 as well as while in 
remission.19 Analyses from our patient cohort are consistent with these previous data in that 
only 7% of patients experienced TRM and 16% died while in CR. Accurate methods to 
predict resistance to standard therapy are needed if physicians are to reliably advise AML 
patients. Specifically, if the ability to predict resistance was sufficiently high, it would be 
difficult to recommend standard therapy to some patients and similarly difficult to 
recommend investigational therapies to others. Experience suggests that these 
recommendations are commonly made; however, they are made in the absence of 
quantitative measurements of predictive ability. While perhaps not surprisingly confirming 
that age, performance status, WBC, secondary disease, cytogenetic risk, and NPM1/FLT3-
ITD mutational status are each strongly and independently associated (P<0.001) with 
resistance, our results suggest that our ability to predict resistance is much less impressive. 
Indeed, using standard criteria relating AUC to predictive ability, this ability is only “fair” 
and is little improved by inclusion of data on aberrations in FLT3 and NPM1; the same was 
true if attention was restricted to more homogeneous subsets such as younger patients or 
those with de novo AML. This finding, denoting only a fair ability to predict CR, is 
reminiscent of a recent study by Krug et al., who observed similar AUCs (0.72 and 0.68) 
with multivariable models in their study cohort, although their definition of primary 
refractory AML were slightly different.20 While some clinicians might understandably feel 
that even fair predictive ability justifies a recommendation that some patients receive 
standard therapy and others investigational therapy, others might feel that the relatively low 
AUCs for resistance support randomization between standard and investigational therapies. 
Thus this study provides a rationale for continued randomization as the best means to 
accurately evaluate the comparative efficacies of new and standard therapies.
Resistance is undoubtedly difficult to predict because AML is an extraordinarily complex 
and heterogeneous disease, whose diversity is only very partially captured by clinical 
parameters, cytogenetic data, and information about aberrations in NPM1 and FLT3, the 
covariates we examined. Mutations in many additional genes may carry prognostic 
significance,21–25 the degree of which may depend on the co-existence of other 
alterations;26 it would therefore be interesting to assess the degree to which AUCs could be 
improved by incorporating data from additional genetic or molecular analyses or pre-
treatment assays that test AML signaling pathways functionally. Moreover, different AML 
subclones may exhibit differential chemotherapy sensitivities, with resistance reflecting 
emergence of subclones whose importance cannot be determined at initial presentation.27 
Emergence of these clones will likely make it more difficult to forecast resistance as the 
period over which the forecast is attempted increases. Such increasing difficulty was seen as 
we moved from predicting primary resistance to predicting primary resistance and RFS. In 
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contrast, our previous efforts to predict death within 28 days of beginning chemotherapy 
were more successful.9 Integration of post-treatment data, e.g. early disease clearance in the 
case of primary refractory AML or achievement of CR vs. CRp/CRi and assessment of 
minimal residual disease,28–33 in the case of RFS may improve prediction of resistance.
While our data are derived from well-annotated patients treated with contemporary AML 
regimens, several limitations need to be acknowledged. First, our results may only apply to 
newly diagnosed AML treated with “3+7” or more intense regimens and may be influenced 
by allogeneic transplantation, about which we have only limited information. Second, rather 
than “harmonizing” cytogenetic risk categories across our study cohort, we used the 
cooperative study group’s separate classification; however, recoding of the SWOG patient 
cohort to the refined MRC/NCRI classification34 only slightly changed the AUC of a 
multivariable prediction model (change from 0.68 to 0.70) and additional categorization of 
patients with monosomal karyotype35 as separate risk entity did not further improve the 
AUC (AUC=0.70). Third, we did not distinguish between relapse and death in CR as events 
contributing to short RFS, a criterion for resistance in some of our analyses. While patients 
who die in CR are not necessarily “resistant”, previous studies indicated that patients who 
die in CR are much more similar to patients who relapse than those who remain alive in 
CR.19 And fourth, we did not use an independent dataset to obtain an unbiased estimate of 
the AUC of any of the models presented in this paper. However, the goal of this paper was 
not to generate one predictive model; rather, our aim was to investigate how the predictive 
ability of a model changes as cytogenetics and molecular information is incorporated into 
the model, and to assess whether there were similar trends across separate cohorts. For this 
purpose, validation via bootstrapping15, 16 provides a useful approach to assess the internal 
model accuracy. Of note, experience suggests that models do not perform as well in 
independent datasets as in the dataset used to derive them. Thus, the use of another dataset is 
unlikely to change our fundamental conclusion (i.e. that the usefulness of current prognostic 
factors for guiding treatment decisions is very likely overestimated), which was supported 
by separate analyses of data from SWOG, MDA, HOVON, and MRC.
In conclusion, our ability to predict therapeutic resistance based on routinely available 
clinical covariates, even with inclusion of commonly used molecular data on FLT3 and 
NPM1, is relatively limited. This finding appears to have significant clinical consequences. 
Not infrequently, multivariate analysis is used to examine whether, after accounting for 
covariates such as cytogenetics, NPM1 and FLT3 status, a new treatment is superior to an 
older one. However if the predictive ability of these covariates is limited as our results 
indicate, reliance on historical controls to assess the new treatment is problematic. Thus, our 
results emphasize the continued importance of randomized treatment assignment for the 
testing of new drugs in AML.
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Figure 1. Prediction of Therapeutic Resistance
Importance of individual covariates to predict (A) failure to achieve CR with initial 1–2 
courses of induction chemotherapy, (B) failure to achieve CR with initial 1–2 courses of 
induction chemotherapy or RFS ≤3 months, (C) failure to achieve CR with initial 1–2 
courses of induction chemotherapy or RFS ≤6 months, and (D) failure to achieve CR with 
initial 1–2 courses of induction chemotherapy or RFS ≤12 months, using χ2 values.
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